May 10, 2016 (Washington, DC) – A rapid increase in the use of wearable technology and an upsurge in social media for patient recruitment are two of the more prevalent clinical trial technology trends, according to a new survey from the Association of Clinical Research Organizations (ACRO). Full details of the survey may be viewed here. “ACRO members are at the forefront of developing and implementing new clinical trial technologies to enhance efficiency and improve the patient experience,” said John Lewis, Senior Vice President, Policy & Public Affairs at ACRO. “But the biopharmaceutical industry is heavily regulated so there are several areas where we are requesting that the Food and Drug Administration consult with stakeholders and provide additional guidance to encourage the adoption of these exciting technologies. We thank the FDA for requesting input on this issue.” Other areas where ACRO members identified substantial benefit/increase in adoption were: risk-based monitoring; electronic informed consent (eConsent); and the use of near real-time trial data analytics. Lewis noted that the FDA has already provided guidance on risk-based monitoring and eConsent and the industry has been actively implementing these tools and technologies. ACRO’s members have invested in developing a variety of real-time clinical trial data analytics platforms which are supporting risk-based monitoring, adaptive trial designs and other innovations. “Individually, these technologies will have a positive impact on clinical trial efficiency,” said Lewis. “But collectively they can help bring about a much more productive process for research sponsors, CROs, sites and patients.” The survey, which formed the basis of ACRO’s comment to the FDA’s public docket, “Using Technologies and Innovative Methods to Conduct FDA-Regulated Clinical Investigations of Investigational Drugs,” was administered by Industry Standard Research.
About ACRO The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics, and medical devices. The Association provides an active voice for the CRO industry globally. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ more than 110,000 professionals worldwide and conduct research in 142 countries. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel. Facebook. RebelMouse.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.